Suppr超能文献

肾母细胞瘤血清蛋白质生物标志物的筛选与鉴定分析

[Screening and identification analysis of serum protein biomarkers in nephroblastoma].

作者信息

Wang Jia-Xiang, Yang Shao-Bo, Liu Qiu-Liang, Dong Rui, Fan Yu-Xia, Zhang Qian, Yang Fu-Quan, Wu Peng, Yu Jie-Kai, Zheng Shu

机构信息

Department of Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

出版信息

Zhonghua Yi Xue Za Zhi. 2009 May 12;89(18):1259-63.

Abstract

OBJECTIVE

To screen and characterize the serum protein biomarkers in nephroblastoma so as to establish the proteins as the specific serum biomarkers for diagnosis and prognosis monitoring.

METHODS

The differential protein peaks were located by detecting serum samples of preoperative and postoperative patients and normal children using the SELDI-TOF MS technology. After purification, the differential proteins were further analyzed by LC-MS/MS and the protein sequences searched in database.

RESULTS

Two peaks with m/z of 6455.5 and 6984.4 were selected as potential biomarkers. They were weakly expressed in nephroblastoma (intensity: 1029 +/- 364, 297 +/- 126) but highly expressed in normal individuals (2108 +/- 837, 753 +/- 226); another peak with m/z of 9190.8 was weakly expressed in preoperative sera (283 +/- 154) but highly expressed in serum samples of postoperative patients and normal children (5974 +/- 657, 6231 +/- 519). The protein at 6455.5 and 9190.8 were identified as apolipoprotein C-III and haptoglobin respectively.

CONCLUSION

The detection of differentially expressed apolipoprotein C-III and haptoglobin may have potential utilities for serum diagnosis, malignancy classification and prognosis monitoring of nephroblastoma and is worthy of further studies and applications.

摘要

目的

筛选并鉴定肾母细胞瘤血清蛋白质生物标志物,将这些蛋白质确立为诊断和预后监测的特异性血清生物标志物。

方法

采用表面增强激光解吸电离飞行时间质谱(SELDI-TOF MS)技术检测术前、术后患者及正常儿童的血清样本,定位差异蛋白峰。纯化后,通过液相色谱-串联质谱(LC-MS/MS)进一步分析差异蛋白,并在数据库中搜索蛋白质序列。

结果

选择质荷比(m/z)为6455.5和6984.4的两个峰作为潜在生物标志物。它们在肾母细胞瘤中表达较弱(强度:1029±364,297±126),而在正常个体中高度表达(2108±837,753±226);另一个m/z为9190.8的峰在术前血清中表达较弱(283±154),但在术后患者和正常儿童的血清样本中高度表达(5974±657,6231±519)。质荷比为6455.5和9190.8的蛋白质分别被鉴定为载脂蛋白C-III和触珠蛋白。

结论

检测差异表达的载脂蛋白C-III和触珠蛋白可能对肾母细胞瘤的血清诊断、恶性分类和预后监测具有潜在应用价值,值得进一步研究和应用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验